Cardax, Inc. – “Nutraceuticals as Pharmaceuticals: Disruptive New Therapeutics from Cardax”

Publishing & Media

Share Tweet

Cardax, Inc. – “Nutraceuticals as Pharmaceuticals: Disruptive New Therapeutics from Cardax”

New York, NY / May 21, 2014 / Cardax, Inc. (OTCQB: CDXI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Scientific Officer, Gilbert M. Rishton, Ph.D. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his guest blog, Dr.Gilbert M. Rishton discusses the need to deliver innovative new ways to "address society's most dramatically unmet medical needs" and why so many companies have failed to do so. He outlines Cardax's "disruptive therapeutic approach" as the Company strives to develop a treatment for chronic and age-related diseases. Read the full blog post from Dr. Gilbert M. Rishton on (

About Cardax

Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration ("FDA") Generally Recognized as Safe ("GRAS") designation at certain doses. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment.

SOURCE: The Chairmans Blog